Advertisement · 728 × 90
#
Hashtag
#exon44skipping
Advertisement · 728 × 90
DMD WarrioR
DMD WarrioR
@dmdwarrior.com
5 months ago
Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026

Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026

Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026

#dmd #duchenne #delzota #exon44 #exon44skipping #clinicaltrials #aviditybiosciences

👉 Read More: DMDWarrioR.com

0 0 0 0
DMD WarrioR
DMD WarrioR
@dmdwarrior.com
6 months ago
Del-zota (Exon 44 Skipping Therapy) Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in Phase 1/2 Trial With del-zota, normal dystrophin increased by 25% and creatine kinase decreased by 80%. Among exon 44 skipping therapies, the highest values ​​currently received have caused excitement. Unprecedented rapid reduction in creatine kinase (CK) to near normal levels maintained over 16 months of follow-up and 25% increase of normal in dystrophin production, reflecting sustained muscle fiber protection.

Del-zota (Exon 44 Skipping Therapy) Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in Phase 1/2 Trial With del-zota, normal dystrophin increased by 25% and creatine kinase decreased by 80%. Among exon 44 skipping therapies, the highest values ​​currently received have caused excitement. Unprecedented rapid reduction in creatine kinase (CK) to near normal levels maintained over 16 months of follow-up and 25% increase of normal in dystrophin production, reflecting sustained muscle fiber protection.

Del-zota (Exon 44 Skipping Therapy) Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in Phase 1/2 Trial

#dmd #duchenne #delzota #exon44 #exon44skipping #clinicaltrials #aviditybiosciences

👉 Read More: DMDWarrioR.com

2 0 0 0
DMD WarrioR
DMD WarrioR
@dmdwarrior.com
1 year ago
Entrada Therapeutics Receives FDA Approval to Begin Clinical Trial of ENTR-601-44 Exon Skipping Treatment Entrada Therapeutics, announced that the United States Food and Drug Administration (FDA) has lifted the clinical hold on ENTR-601-44 and provided authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose (MAD) clinical study of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy (DMD) in adult patients with a confirmed mutation in the DMD gene amenable to exon 44 skipping.

Entrada Therapeutics Receives FDA Approval to Begin Clinical Trial of ENTR-601-44 Exon Skipping Treatment Entrada Therapeutics, announced that the United States Food and Drug Administration (FDA) has lifted the clinical hold on ENTR-601-44 and provided authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose (MAD) clinical study of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy (DMD) in adult patients with a confirmed mutation in the DMD gene amenable to exon 44 skipping.

Entrada Therapeutics Receives FDA Approval to Begin Clinical Trial of ENTR-601-44 Exon Skipping Treatment

👉 Read More: dmdwarrior.com

#dmd #duchenne #exon44 #exon44skipping #exonskipping

1 0 0 0
DMD WarrioR
DMD WarrioR
@dmdwarrior.com
1 year ago
Entrada Therapeutics Receives UK Authorization to Begin ELEVATE-44-201 (Exon 44 Skipping) Entrada Therapeutics Receives UK Authorization to Begin ELEVATE-44-201 (Exon 44 Skipping Treatment), a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Duchenne Muscular Dystrophy Patients. ELEVATE-44-201, a Phase 1/2 multiple ascending dose (MAD) clinical study of ENTR-601-44, was authorized by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee for the Clinical Trial of an Investigational Medicinal Product. The study aims to treat Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation in the DMD gene that is amenable to exon 44 skipping.

Entrada Therapeutics Receives UK Authorization to Begin ELEVATE-44-201 (Exon 44 Skipping) Entrada Therapeutics Receives UK Authorization to Begin ELEVATE-44-201 (Exon 44 Skipping Treatment), a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Duchenne Muscular Dystrophy Patients. ELEVATE-44-201, a Phase 1/2 multiple ascending dose (MAD) clinical study of ENTR-601-44, was authorized by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee for the Clinical Trial of an Investigational Medicinal Product. The study aims to treat Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation in the DMD gene that is amenable to exon 44 skipping.

Entrada Therapeutics Receives UK Authorization to Begin ELEVATE-44-201 (Exon 44 Skipping)

👉 Read More: dmdwarrior.com

#duchenne #dmd #duchennemusculardystrophy #dmdwarrior #duchenneawareness #uk #england #exon44skipping #entrada

1 0 0 0